Skip to main content
Top
Published in: Arthritis Research & Therapy 1/1999

01-12-1999 | Paper Report

CD40 regulates rheumatoid factor production

Author: Gerry Wilson

Published in: Arthritis Research & Therapy | Issue 1/1999

Login to get access

Excerpt

High affinity autoantibodies specific for the Fc regions of IgG are known as rheumatoid factors (RFs) and occur in the major of adults with rheumatoid arthritis (RA). The mechanisms behind the survival of these autoantibodies are not known, as it would be expected that cross-linking of Ig on the surface of a B cell would lead to anergy of deletion. Previous studies have, however, suggested that T cell help, delivered around the time of surface Ig cross-linking on B cells, leads to activation and secretion of higher affinity RFs. To identify the factor(s) required for the survival and differentiation of murine B cells transgenic for pathogenic high affinity human RF. …
Literature
1.
go back to reference Kyburz K, Corr M, Brinson DC, Von Damm A, Tighe H, Carson DA: Human rheumatoid factor production is dependent on CD40 signaling and autoantigen. J Immunol. 1999, 163: 3116-3122.PubMed Kyburz K, Corr M, Brinson DC, Von Damm A, Tighe H, Carson DA: Human rheumatoid factor production is dependent on CD40 signaling and autoantigen. J Immunol. 1999, 163: 3116-3122.PubMed
Metadata
Title
CD40 regulates rheumatoid factor production
Author
Gerry Wilson
Publication date
01-12-1999
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/1999
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar-1999-66745

Other articles of this Issue 1/1999

Arthritis Research & Therapy 1/1999 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine